Evidence map›Paper›PMID 38081879›Full record

ArticleScientific reports2023

Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.

Ting Zhou, Zhiqiang Ke, Qianqian Ma, Jiani Xiang, Meng Gao, Yongqi Huang, Xiyao Cheng, Zhengding Su

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ting Zhou *School of Light Industry and Food Engineering, Guangxi University, No. 100, Daxuedong Road, Xixiangtang District, Nanning, 530004, Guangxi, China.
Zhiqiang Ke *Protein Engineering and Biopharmaceutical Sciences Group, Hubei University of Technology, Wuhan, 430068, China.
Qianqian MaProtein Engineering and Biopharmaceutical Sciences Group, Hubei University of Technology, Wuhan, 430068, China.
Jiani XiangProtein Engineering and Biopharmaceutical Sciences Group, Hubei University of Technology, Wuhan, 430068, China.
Meng GaoProtein Engineering and Biopharmaceutical Sciences Group, Hubei University of Technology, Wuhan, 430068, China.
Yongqi HuangProtein Engineering and Biopharmaceutical Sciences Group, Hubei University of Technology, Wuhan, 430068, China.
Xiyao ChengSchool of Light Industry and Food Engineering, Guangxi University, No. 100, Daxuedong Road, Xixiangtang District, Nanning, 530004, Guangxi, China. xiyaocheng@gxu.edu.cn.ORCID 0000-0003-2161-1743
Zhengding SuProtein Engineering and Biopharmaceutical Sciences Group, Hubei University of Technology, Wuhan, 430068, China. zhengdingsu@hbut.edu.cn.ORCID 0000-0003-3558-001X
Hubei University of Technology · CNGuangxi University · CNHubei University of Science and Technology · CN

Funding

Guangxi University Initialtives 2023-2026Hubei Province Education Office Fund Project B20212244Hubei University of Technology 2013-2023Natural Science Foundation of China 32301020
6 · The paper itself

Abstract

The tumor suppressor p53 (p53) is regulated by murine double minute 2 (Mdm2) and its homologous MdmX in maintaining the basal level of p53. Overexpressed Mdm2/MdmX inhibits cellular p53 activity, which is highly relevant to cancer occurrence. Coiled-coil domain-containing protein 106 (CCDC106) has been identified as a p53-interacting partner. However, the molecular mechanism of the p53/Mdm2/MdmX/CCDC106 interactions is still elusive. Here, we show that CCDC106 functions as a signaling regulator of the p53-Mdm2/MdmX axis. We identified that CCDC106 directly interacts with the p53 transactivation domain by competing with Mdm2 and MdmX. CCDC106 overexpression downregulates the cellular level of p53 and Mdm2/MdmX, and decreased p53 reversibly downregulates the cellular level of CCDC106. Our work provides a molecular mechanism by which CCDC106 regulates the cellular levels of p53 and Mdm2/MdmX.

Indexed as

NeoplasmsProto-Oncogene Proteins c-mdm2AnimalsCarrier ProteinsCell Cycle ProteinsHumansMiceProto-Oncogene ProteinsTumor Suppressor Protein p53Carrier ProteinsCCDC106 protein, humanCell Cycle ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53

Identifiers

PMID38081879
PMCPMC10713525
OpenAlexW4389547816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.